StockNews.com Downgrades Voyager Therapeutics (NASDAQ:VYGR) to Hold

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday.

Other equities research analysts have also issued reports about the company. Citigroup began coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price target for the company. HC Wainwright began coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Guggenheim began coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target for the company. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Get Our Latest Analysis on VYGR

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $8.48 on Monday. Voyager Therapeutics has a twelve month low of $6.06 and a twelve month high of $14.34. The business has a 50-day moving average price of $8.80 and a 200 day moving average price of $8.09. The firm has a market cap of $461.21 million, a PE ratio of 2.74 and a beta of 0.98.

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, topping the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The company had revenue of $90.06 million during the quarter, compared to analyst estimates of $4.95 million. On average, sell-side analysts expect that Voyager Therapeutics will post -1.64 EPS for the current year.

Institutional Trading of Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Gladius Capital Management LP acquired a new stake in shares of Voyager Therapeutics during the third quarter valued at about $25,000. Ameritas Investment Partners Inc. lifted its position in shares of Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the last quarter. AJOVista LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter worth about $39,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Voyager Therapeutics during the fourth quarter worth about $43,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Voyager Therapeutics by 302.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,399 shares of the company’s stock worth $54,000 after purchasing an additional 4,809 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Further Reading

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.